ArticleAmerican journal of translational research2019
Effect of bevacizumab on the tight junction proteins of vascular endothelial cells.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- From mechanisms to practice: risk management and multidisciplinary decision-making for systemic treatment-related liver injury in HBV-associated hepatocellular carcinoma.Frontiers in pharmacology · 2026Review
- Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.medRxiv : the preprint server for health sciences · 2025Article
- PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib.Frontiers in oncology · 2025Article
- Tight junctional protein family, Claudins in cancer and cancer metastasis.Frontiers in oncology · 2025Review
- Integration of scRNA and bulk RNA-sequence to construct the 5-gene molecular prognostic model based on the heterogeneity of thyroid carcinoma endothelial cell.Acta biochimica et biophysica Sinica · 2024Article
- miR-4739 promotes epithelial-mesenchymal transition and angiogenesis in "driver gene-negative" non-small cell lung cancer via activating the Wnt/β-catenin signaling.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.Cancer medicine · 2023Article
- Article
- Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4.Journal of cellular and molecular medicine · 2022Article
- Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab.Frontiers in oncology · 2022Article
- Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance.International journal of molecular sciences · 2021Review
- Tight Junction Modulating Bioprobes for Drug Delivery System to the Brain: A Review.Pharmaceutics · 2020Review
- Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathwaysCancer biology & medicine · 2020Article
- anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.Cell death & disease · 2020Article
- Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of anti-angiogenesis and chemotherapy can significantly prolong the survival period of patients with non-squamous non-small cell lung cancer (NSCLC). But drug resistance will inevitably occur, thereby causing increased tumor invasion and metastasis. Claudin-5 (CLDN5) is a protein member of tight junction (TJ) structures expressed in endothelial and epithelial cells and confirmed to be involved in the proliferation and leakage of endothelial cells (ECs) and malignant metastases. This study aimed to investigate how bevacizumab, a vascular endothelial growth factor A (VEGFA) neutralizing antibody applied in clinic, affects the tight junction protein CLDN5 and subsequently influences tumor cell invasion and potential metastasis. Western-blot, quantitative real-time polymerase chain reaction (q-PCR), immunofluorescence and immunohistochemistry revealed that low-dose bevacizumab up-regulated CLDN5, whereas high-dose bevacizumab down-regulated CLDN5. Cell migration, invasion and permeation assay demonstrated that high-dose bevacizumab enhanced the migration, invasion and permeation abilities of human umbilical vein endothelial cells (HUVECs). The migration and permeation abilities of HUVECs were also enhanced by silencing the CLDN5 expression. CLDN5 was regulated by JNK, PI3K and transforming growth factor-β-1 (TGFβ1), and these findings were confirmed by the inhibitor or siRNA of JNK, PI3K and TGFβ1. Our data indicated that high-dose bevacizumab likely increased tumor invasion and potential metastatic abilities by down-regulating CLDN5, which was down regulated by TGFβ1. Low-dose bevacizumab increased CLDN5 expression by up-regulating PI3K and JNK expression.
Indexed as
Identifiers
31632528PMC6789270W2981767523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.